FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care | CPT PPP Coverage
Cryptopolytech (CPT) Public Press Pass (PPP)
News of the Day COVERAGE
200000048 – World Newser
•| #World |•| #Online |•| #Media |•| #Outlet |
View more Headlines & Breaking News here, as covered by cryptopolytech.com
FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care appeared on www.labpulse.com by LabPulse.com.
The U.S. Food and Drug Administration (FDA) on Friday granted an emergency use authorization (EUA) for the Cepheid Xpert Mpox test for use in a point-of-care setting.
The Xpert Mpox test is a real-time polymerase chain reaction (PCR) assay to detect Mpox virus DNA in lesion swab specimens from individuals suspected of having monkeypox by their healthcare provider.
Validation data was gathered through the National Institutes of Health (NIH) Independent Test Assessment Program established as a collaboration between the FDA and the NIH.
The EUA is the latest example of the FDA’s ongoing commitment to advance greater consumer access to tests for infectious diseases, the agency said.
FEATURED ‘News of the Day’, as reported by public domain newswires.
View ALL Headlines & Breaking News here.
Source Information (if available)
This article originally appeared on www.labpulse.com by LabPulse.com – sharing via newswires in the public domain, repeatedly. News articles have become eerily similar to manufacturer descriptions.
We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.
CPT (CryptoPolyTech) PPP (Public Press Pass) Coverage features stories and headlines you may not otherwise see due to the manipulation of mass media.
First to share? If share image does not populate, please close the share box & re-open or reload page to load the image, Thanks!